<code id='07DECD4A90'></code><style id='07DECD4A90'></style>
    • <acronym id='07DECD4A90'></acronym>
      <center id='07DECD4A90'><center id='07DECD4A90'><tfoot id='07DECD4A90'></tfoot></center><abbr id='07DECD4A90'><dir id='07DECD4A90'><tfoot id='07DECD4A90'></tfoot><noframes id='07DECD4A90'>

    • <optgroup id='07DECD4A90'><strike id='07DECD4A90'><sup id='07DECD4A90'></sup></strike><code id='07DECD4A90'></code></optgroup>
        1. <b id='07DECD4A90'><label id='07DECD4A90'><select id='07DECD4A90'><dt id='07DECD4A90'><span id='07DECD4A90'></span></dt></select></label></b><u id='07DECD4A90'></u>
          <i id='07DECD4A90'><strike id='07DECD4A90'><tt id='07DECD4A90'><pre id='07DECD4A90'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:hotspot    - browse:88544

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot